Annals of Clinical and Translational Neurology (Oct 2024)

Overlap of spike and ripple propagation onset predicts surgical outcome in epilepsy

  • Saeed Jahromi,
  • Margherita A.G. Matarrese,
  • Lorenzo Fabbri,
  • Eleonora Tamilia,
  • M. Scott Perry,
  • Joseph R. Madsen,
  • Jeffrey Bolton,
  • Scellig S.D. Stone,
  • Phillip L. Pearl,
  • Christos Papadelis

DOI
https://doi.org/10.1002/acn3.52156
Journal volume & issue
Vol. 11, no. 10
pp. 2530 – 2547

Abstract

Read online

Abstract Objective Interictal biomarkers are critical for identifying the epileptogenic focus. However, spikes and ripples lack specificity while fast ripples lack sensitivity. These biomarkers propagate from more epileptogenic onset to areas of spread. The pathophysiological mechanism of these propagations is elusive. Here, we examine zones where spikes and high frequency oscillations co‐occur (SHFO), the spatiotemporal propagations of spikes, ripples, and fast ripples, and evaluate the spike–ripple onset overlap (SRO) as an epilepsy biomarker. Methods We retrospectively analyzed intracranial EEG data from 41 patients with drug‐resistant epilepsy. We mapped propagations of spikes, ripples, and fast ripples, and identified their onset and spread zones, as well as SHFO and SRO. We then estimated the SRO prognostic value in predicting surgical outcome and compared it to onset and spread zones of spike, ripple, and fast ripple propagations, and SHFO. Results We detected spikes and ripples in all patients and fast ripples in 12 patients (29%). We observed spike and ripple propagations in 40 (98%) patients. Spike and ripple onsets overlapped in 35 (85%) patients. In good outcome patients, SRO showed higher specificity and precision (p < 0.05) in predicting resection compared to onset and zones of spikes, ripples, and SHFO. Only SRO resection predicted outcome (p = 0.01) with positive and negative predictive values of 82% and 57%, respectively. Interpretation SRO is a specific and precise biomarker of the epileptogenic zone whose removal predicts outcome. SRO is present in most patients with drug‐resistant epilepsy. Such a biomarker may reduce prolonged intracranial monitoring and improve outcome.